Study of amivantamab for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called amivantamab, either alone or with other treatments, for people with head and neck cancer that has spread or come back. The goal is to see if the drug can help shrink tumors or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your head and neck cancer must have spread or returned and cannot be cured with local treatments like surgery.
- You must be able to perform daily activities with little or no help (ECOG score 0-1).
- Your blood cell counts and organ function must meet certain levels.
- Any side effects from previous cancer treatments must have mostly resolved.
- You cannot have untreated brain or spinal cord problems or a history of lung disease like fibrosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug amivantamab to usual treatments helps people with advanced head and neck cancer that has come back or spread. It compares the combination to standard care alone.
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
This trial tests a new combination of two drugs (telisotuzumab adizutecan and pembrolizumab) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination can help control the cancer and to find the best dose.
This trial tests a new drug (amivantamab) combined with two chemotherapy drugs (carboplatin and paclitaxel) for people with head and neck cancer that has spread or come back after treatment and cannot be removed by surgery. This study aims to see if this combination can help shrink tumors.
This study tests a new drug called amivantamab for penile cancer that has spread and hasn't responded to earlier treatments. The drug may block signals that help cancer grow. The study also looks at how the HPV virus affects treatment response.
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
Hear when a new Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.